Hair Loss in Women: Causes, Types, and Treatment Options

Hair Loss Affects Millions of Women — and Few Talk About It

Over 50% of women will experience noticeable hair thinning at some point in their lives, with peak prevalence during the postpartum period, perimenopause, and after age 50. Yet because female hair loss lacks the cultural visibility of male pattern baldness — and because many women feel shame about it — the condition is chronically underdiagnosed and undertreated.

Types of Hair Loss in Women

1. Female Pattern Hair Loss (FPHL)

The most common form, affecting approximately 12% of women by age 29, rising to 50%+ by age 60. FPHL presents as diffuse thinning over the crown and top of the scalp — with the frontal hairline often preserved. Driven by genetic sensitivity of hair follicles to androgens (particularly DHT). Importantly, most women with FPHL do not have elevated androgen levels — their follicles are simply more sensitive to normal circulating androgens.

2. Telogen Effluvium

A reactive condition triggered by significant physiological stress — causing a disproportionate number of hairs to shift into the resting phase and shed. Common triggers: childbirth (peaks 3–6 months postpartum), rapid weight loss, major surgery or illness, severe emotional stress, nutritional deficiencies (particularly iron and ferritin), thyroid disease, and hormonal contraceptive changes. Typically self-resolving once the trigger is addressed, but may take 6–12 months for full recovery.

3. Alopecia Areata

An autoimmune condition causing patchy hair loss from immune attack on follicles. Recent advances, particularly JAK inhibitors, have dramatically improved outcomes. Learn more in our guide to alopecia areata treatment options.

4. Traction Alopecia

Chronic mechanical tension from tight hairstyles (braids, tight ponytails, extensions). Initially reversible if the style is changed, but may become permanent if tension is sustained for years.

5. Frontal Fibrosing Alopecia (FFA)

A scarring alopecia with progressive frontal hairline recession — often with loss of eyebrows and eyelashes. Predominantly affects postmenopausal women. Treatment aims to stop progression; early diagnosis is critical.

6. Nutrient Deficiency-Related Hair Loss

Key deficiencies contributing to female hair loss:

• Iron/ferritin: Low ferritin (below 30–40 ng/mL) is associated with chronic telogen effluvium — the most commonly missed cause of female hair loss.
• Vitamin D: Receptors in hair follicles play a role in the hair cycle; deficiency associated with shedding.
• Zinc: Supports keratin synthesis and follicle function.
• Protein: Hair is primarily keratin; inadequate intake impairs growth.

Diagnostic Evaluation

A thorough workup typically includes: CBC, iron studies with ferritin, TSH, free T4, testosterone (total and free), DHEA-S, estradiol, vitamin D, zinc, and metabolic panel. Scalp examination with dermoscopy allows precise pattern classification.

Treatment Options

Minoxidil

FDA-approved for female pattern hair loss. Available as 2% topical solution, 5% foam, or oral minoxidil (off-label, 0.25–1.25 mg daily). Response takes 4–6 months of consistent use to assess. Our guide to hair loss treatments for women covers this in depth.

Spironolactone

Anti-androgen blocking DHT receptors at the follicle. Off-label but widely used for FPHL, particularly in women with signs of hyperandrogenism. Doses 50–200 mg daily; must be used with contraception in premenopausal women.

Finasteride / Dutasteride

5-alpha reductase inhibitors reducing DHT production. Used off-label in postmenopausal women for FPHL. Cannot be used by women who may become pregnant. Dutasteride may be more effective than finasteride for female androgenetic alopecia.

Platelet-Rich Plasma (PRP)

Patient's own blood drawn, processed to concentrate growth factors, then injected into the scalp. Evidence supports PRP for androgenetic alopecia — multiple studies show improvements in hair density. Requires maintenance injections every 3–6 months.

Low-Level Laser Therapy (LLLT)

FDA-cleared devices (caps, helmets, combs) delivering red/near-infrared light stimulate follicular metabolism. Multiple clinical trials show modest but significant improvements in hair density. Suitable for consistent home use.

Hormonal Optimization

In perimenopausal and postmenopausal women, hormone replacement therapy — particularly estrogen — may slow or partially reverse FPHL. A licensed provider can evaluate hormone status and determine whether HRT benefits hair health alongside other symptoms.

When to Seek Evaluation

Progressive, widespread hair loss associated with scalp symptoms or other systemic symptoms warrants prompt medical evaluation. Early intervention — before significant follicle miniaturization or scarring — yields the best outcomes. Begin with a telehealth consultation through our hair loss program.